Guizhou Sanli Pharmaceutical Co., Ltd.’s announcement on the progress of marketing authorization of transferred drugs
Securities code: 603439 Securities abbreviation: Sanli Pharmaceutical Announcement number: 2026-039 Guizhou Sanli Pharmaceutical Co., Ltd.
Announcement on the progress of marketing authorization of transferred drugs
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Recently, Guizhou Sanli Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received the "Drug Supplementary Application Approval Notice" approved and issued by the State Food and Drug Administration, agreeing to change the marketing authorization holder of Cisplatin Sodium Chloride Injection to the company.
1. Transaction Overview
The company and Guizhou Hanfang Pharmaceutical Co., Ltd. (hereinafter referred to as "Kanfang Pharmaceutical") signed the "Drug Marketing Authorization Holder Transfer Agreement" in April 2026, agreeing that Kamfang Pharmaceutical will transfer the marketing licenses and related rights and interests of 16 drugs it holds to the company, among which Cisplatin Sodium Chloride Injection (National Drug Approval Number H20020273) is the core product of this transfer. The total transfer price (including tax) is RMB 2 million. For details, please refer to the "Announcement of Guizhou Sanli Pharmaceutical Co., Ltd. on the Signing of the "Drug Marketing Authorization Holder Transfer Agreement" disclosed by the company on April 2, 2026 (Announcement Number: 2026-007).
2. Transaction progress
The company recently received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, agreeing to change the marketing authorization holder of Cisplatin Sodium Chloride Injection from Kampo Pharmaceutical to the company. The specific situation is as follows:
Drug name: Cisplatin Sodium Chloride Injection
Dosage form: injection
Specifications: 50ml: 50mg cisplatin and 450mg sodium chloride
Registration Category: Chemicals
Notice number: 2026B03387
Approval number: National Drug Approval No. H20020273
Approval conclusion: In accordance with the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, the application for this product meets the relevant requirements for drug registration. It is agreed to approve the holding of the marketing license for this product in accordance with the relevant provisions of the "Measures for the Administration of Post-Market Changes in Drugs (Trial)" The name of the company was changed from "Guizhou Hanfang Pharmaceutical Co., Ltd. (Address: No. 1, Hanfang Road, Xiayanglang Village, Yongjing Town, Xifeng County, Guiyang City, Guizhou Province)" to "Guizhou Sanli Pharmaceutical Co., Ltd. (Address: Xiayun Industrial Park, Pingba District, Anshun City, Guizhou Province)", and the drug approval number remains unchanged. The production site, prescription, production process, quality standards, etc. of the transferred drugs are consistent with the original drugs and will not be changed. The transferred drugs can be marketed and sold if they meet the product release requirements after passing the Good Manufacturing Practice compliance inspection.
3. Impact on the company and risk warning
The marketing authorization holder of Cisplatin Sodium Chloride Injection has been officially changed to the company, which is in line with the company's mid- to long-term development strategy. In the future, it may help enrich the company's oncology drug product line and further enhance market competitiveness. The above matters will not have a significant impact on the company's current financial status and operating results.
Pharmaceutical sales are easily affected by industry policies, bidding and procurement, market environment and other factors, and there are uncertainties. The company will follow up on the specific progress and fulfill its information disclosure obligations in a timely manner in accordance with relevant regulations. Investors are kindly requested to pay attention to investment risks and make rational decisions.
Announcement is hereby made.
Board of Directors of Guizhou Sanli Pharmaceutical Co., Ltd.
June 9, 2026